Abcam Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
2,313
- Latest Deal Type
-
M&A
- Financing Rounds
-
8
- Investments
-
16
Abcam General Information
Description
Provider of discovery and research technology services intended to serve life science researchers. The company provides products that allow research into the role of signaling and regulatory molecules and proteins in biological pathways, enabling clients to avail solutions that lead to treatments for diseases such as cancer and immune deficiency disorders.
Contact Information
Website
www.corporate.abcam.com(Operating Subsidiary)
Corporate Office
- Discovery Drive
- Cambridge Biomedical Campus
- Cambridge CB2 0AX
- England, United Kingdom
Corporate Office
- Discovery Drive
- Cambridge Biomedical Campus
- Cambridge CB2 0AX
- England, United Kingdom
Abcam Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Abcam Comparisons
Industry
Financing
Details
Abcam Competitors (42)
One of Abcam’s 42 competitors is Sphere Fluidics, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sphere Fluidics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| EpiGentek | Corporation | Farmingdale, NY | ||||
| PeproTech | Corporate Backed or Acquired | Cranbury, NJ | ||||
| System Biosciences | Venture Capital-Backed | Palo Alto, CA | ||||
| Origene | Formerly VC-backed | Rockville, MD |
Abcam Patents
Abcam Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-2629129-A | M6a antibody | Pending | 09-Jan-2023 | ||
| GB-202012722-D0 | Validation method | Inactive | 14-Aug-2020 | ||
| EP-3661958-A2 | Methods and compositions for the development of antibodies specific to epitope post-translational modification status | Inactive | 04-Aug-2017 | ||
| JP-2020534797-A | Ligand-oriented antibody design methods and compositions | Pending | 04-Aug-2017 | ||
| JP-2020534796-A | Epitope post-translational modification state-specific antibody development method and composition for development | Pending | 04-Aug-2017 | C07K16/44 |
Abcam Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abcam Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Abcam Investments & Acquisitions (16)
Abcam’s most recent deal was a Merger/Acquisition with BioVision for . The deal was made on 26-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BioVision | 26-Oct-2021 | Merger/Acquisition | Biotechnology | ||
| ViaNautis | 29-Mar-2021 | Early Stage VC | Biotechnology | ||
| Marker Gene Technologies | 04-Mar-2020 | Merger/Acquisition | Biotechnology | ||
| Applied StemCell (Gene Editing Platform and Oncology Product Portfolio) | 30-Jan-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Innova Biosciences | 01-Jan-2020 | Merger/Acquisition | Pharmaceuticals |
Abcam Exits (1)
Abcam’s most recent exit was on 07-Apr-2008 from Horizon Discovery. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Horizon Discovery | 07-Apr-2008 | Completed |
|
Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Abcam (Netherlands) | Amsterdam, Netherlands | 2018 | |
| Expedeon Holdings | Cambridge, United Kingdom | 2009 | |
| Ascent Scientific | Bristol, United Kingdom | 2005 | |
| TGR BioSciences | Thebarton, Australia | 2001 |
Abcam FAQs
-
When was Abcam founded?
Abcam was founded in 1998.
-
Where is Abcam headquartered?
Abcam is headquartered in Cambridge, United Kingdom.
-
What is the size of Abcam?
Abcam has 2,313 total employees.
-
What industry is Abcam in?
Abcam’s primary industry is Discovery Tools (Healthcare).
-
Is Abcam a private or public company?
Abcam is a Private company.
-
What is the current valuation of Abcam?
The current valuation of Abcam is .
-
What is Abcam’s current revenue?
The current revenue for Abcam is .
-
How much funding has Abcam raised over time?
Abcam has raised $457M.
-
Who are Abcam’s investors?
Beringea, Martlet Capital, and T. Rowe Price Group have invested in Abcam.
-
Who are Abcam’s competitors?
Sphere Fluidics, EpiGentek, PeproTech, System Biosciences, and Origene are some of the 42 competitors of Abcam.
-
When was Abcam acquired?
Abcam was acquired on 06-Dec-2023.
-
Who acquired Abcam?
Abcam was acquired by Danaher.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
